Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/30991
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18076/20274 (89%)
造访人次 : 4614174      在线人数 : 1122
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/30991


    標題: The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer
    作者: Chang, Wei-Ting
    Shih, Jhih-Yuan
    Feng, Yin-Hsun
    Chiang, Chun-Yen
    Kuo, Yu Hsuan
    Chen, Wei-Yu
    Wu, Hong-Chang
    Cheng, Juei-Tang
    Wang, Jhi-Joung
    Chen, Zhih-Cherng
    貢獻者: Chi Mei Med Ctr, Div Cardiol, Dept Internal Med
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Chi Mei Med Ctr, Dept Internal Med, Div Oncol
    Chi Mei Med Ctr, Dept Med Res
    Chia Nan Univ Pharm & Sci, Dept Pharm
    關鍵字: Dyspnea
    Epirubicin
    Right ventricle
    Speckle-tracking echocardiography
    dysfunction
    日期: 2016-09
    上傳時間: 2018-01-18 11:39:23 (UTC+8)
    出版者: Taiwan Soc Cardiology
    摘要: Background: As cancer therapies have improved, patient life spans have been extended but quality of life has been threatened by chemotherapy induced cardiotoxicity. Most cardiac complications remain unobserved until specific symptoms develop. Speckle-tracking echocardiography is a sensitive imaging modality in detecting early occult myocardial dysfunction. Methods: A total number of 35 patients newly diagnosed with breast cancer and preparing for epirubicin therapy were prospectively recruited. Echocardiography, including speckle-tracking echocardiography, was performed sequentially at baseline (T1), after the first cycle (T2) and after the third cycle (T3) of epirubicin. At each visit, the severity of dyspnea was evaluated by the assessment scale. Results: Compared with the baseline, right ventricular longitudinal strain (RVLS_FW) at T2 significantly declined (-22.49 +/- 4.97 vs. -18.48 +/- 4.46, p = 0.001), which was also positively associated with the development of dyspnea (R-2 = 0.8, p = 0.01). At T3, both the left ventricular global longitudinal strain and RVLS_FW were significantly impaired (-21.4 +/- 4.12 vs.-16.94 +/- 6.81%; -22.49 +/- 4.97 vs. -16.86 +/- 7.27%, p = 0.01; 0.001, respectively). Also, the accumulating dose of epirubicin positively correlated with the development of dyspnea (R-2 = 0.38, p = 0.04) and the decline of RVLS_FW (R-2 = 0.53, p = 0.02). Notably, compared with the other echocardiographic parameters only RVLS_FW at the early stage (T2) significantly correlated with the development of dyspnea (odds ratio: 1.84, 95% confidence interval: 1.22-2.78, p = 0.04). Conclusions: RVLS_FW sensitively predicts dyspnea development in breast cancer patients receiving epirubicin therapy. However, larger scale studies are required to validate its role in long-term patient survival.
    關聯: Acta Cardiologica Sinica, v.32 n.5, pp.550-559
    显示于类别:[藥學系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    30991.pdf544KbAdobe PDF370检视/开启
    index.html0KbHTML1221检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈